Published
Scott B. Sellinger, MD, FACS, President of Advanced Urology Institute in Tallahassee, Florida, addresses key considerations in deciding between doublet and triplet therapies for metastatic castration-sensitive prostate cancer. In this 12-minute presentation, Dr. Sellinger highlights the superiority of androgen deprivation therapy (ADT) combined with androgen pathway inhibitors, offering superior survival benefits compared to ADT alone.
- Category
- Urology
Be the first to comment
Up Next
-
05:13
So Special: A look at CAR T-Cell Therapy at SickKids
-
19:53
Andrew Tate goes to therapy #6 - (Therapist Reacts)
-
15:54
The psychology of self-motivation | Scott Geller | TEDxVirginiaTech
-
09:38
I Quit Therapy| Black Psychologist
-
17:45
Demystifying psychodynamic therapy
-
12:32
Hormone Replacement Therapy in Menopause
-
09:15
Patient Characteristics to Consider for Doublet, Triplet Therapy in mHSPC and mCRPC
-
05:48
Implementing Triplet Therapy for mHSPC: Collaboration, Patient Communication, and QOL Considerations
-
18:07
Let's talk weaponization of "therapy-speak"
-
05:13
Applications of SiRNA for cancer therapy
-
09:07
Cardiology for Beginners: Basics of Heart Sounds and Murmurs (with examples)
-
13:45
How to Become a Cardiologist | Cardiac Electrophysiologist
-
04:14
V 00592 Cardiology Fellowship Video Dr Vranian V5
-
05:17
Cardiology Fellowship at SIU Medicine
-
04:15
Cardiology Fellowship Program at Danbury Hospital
-
05:49
Practice Question: Cardiology #1, USMLE Step 1, COMLEX Level 1
-
04:07
Dr. Muhammed Raza on advice for Fellows interested in Interventional Cardiology
-
07:36
Congenital Heart Disease – Cardiology | Lecturio
-
05:18
Cardiology Fellowship at IU School of Medicine
-
04:36
What are different types of Cardiology Tests | SPS Hospitals
